StockWatch
·
Pharmaceuticals
Quarterly Result15 Feb 2026, 05:31 am

Everest Organics Approves Q3 and Nine Months Results for 2025, Despite Production Capacity Concerns and Pending Liabilities

AI Summary

Everest Organics Limited has approved its unaudited financial results for the quarter and nine months ended December 31, 2025. The company reported a sales turnover of Rs 5026.85 Lakhs, with domestic sales at Rs.3970.75 Lakhs and export sales at Rs. 1056.10 Lakhs. However, the company is operating at a higher production capacity without necessary approvals from the Telangana State Pollution Control Board (TSPCB), which could impact its going concern status. Additionally, the company has not recognized Rs.143 lakhs in interest expenses towards delayed payments to suppliers, nor has it determined the additional employee benefit obligation from the implementation of the New Labour Codes. The company's stock secretary and compliance officer, Shweta Singh, announced the results.

Key Highlights

  • Everest Organics reported a sales turnover of Rs 5026.85 Lakhs for Q3 2025.
  • The company's domestic sales stood at Rs.3970.75 Lakhs, while export sales were at Rs. 1056.10 Lakhs.
  • The company is operating at a higher production capacity without necessary approvals from the TSPCB, which could impact its going concern status.
  • Everest Organics has not recognized Rs.143 lakhs in interest expenses towards delayed payments to suppliers.
  • The company has not determined the additional employee benefit obligation from the implementation of the New Labour Codes.